Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

By Michael Erman (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's BioNTech on an ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...